foxo4-dri senolytic peptide human trial 2024 FOX04-DRI FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI UK Senolytic Peptide Research Peptides Lab UK FOXO4 peptide targets myofibroblast ameliorates bleomycininduced pulmonary fibrosis in mice through ECMreceptor interaction pathway Han 2022 Journal of Cellular and Molecular Medicine Wiley Online Library
Pay in 4 interest-free payments of $5.07 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




